TNIK Therapeutics

Company Overview

Snapshot

Founded in May 2018, TNIK Therapeutics operates with 1–10 employees. The company secured funding in one round from FuturX in January 2019. TNIK Therapeutics ceased operations in August 2022.

Business overview

TNIK Therapeutics is a Health Tech & Life Sciences company focused on developing small molecule inhibitors for TNIK, a key transcription regulator in the Wnt pathway. This pathway is a significant driver of colorectal carcinogenesis when over-activated. The company's technology targets the beta-catenin-TCF4 transcription complex to regulate genes crucial for stemness and proliferation, aiming for reduced off-target effects compared to other transcription regulators. TNIK Therapeutics operates in the Pharmaceuticals sector, specifically in Drugs Discovery & Development, serving the Life Sciences and Pharmaceuticals markets with a B2B business model.

Strategic signal

In February 2019, Severance Hospital transferred a colorectal cancer treatment candidate to TNIK Therapeutics, signaling a strategic move to advance its pipeline in cancer therapeutics. This collaboration highlights the company's focus on leveraging external research for the development of small molecule inhibitors targeting TNIK, a critical pathway in colorectal cancer.

Company Intelligence Q&A

What is TNIK Therapeutics' primary focus?

TNIK Therapeutics focuses on developing small molecule inhibitors of TNIK, a downstream transcription regulator of the Wnt pathway, to target cancer stem cell diseases, particularly colorectal carcinogenesis.

When did TNIK Therapeutics cease operations?

TNIK Therapeutics ceased to operate in August 2022.

What was a significant early development for TNIK Therapeutics?

In February 2019, Severance Hospital transferred a colorectal cancer treatment candidate to TNIK Therapeutics, indicating a key step in the company's drug development efforts.

Which institution provided an exclusive license to TNIK Therapeutics?

TNIK Therapeutics obtained an exclusive license from the Korea Research Institute of Chemical Technology and Yonsei University Health System for the development of small molecule inhibitors to TNIK.

What is the business model of TNIK Therapeutics?

TNIK Therapeutics operates with a B2B business model, serving the Life Sciences and Pharmaceuticals markets.